STOCK TITAN

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in TIL therapies for cancer patients, has granted inducement stock options to two new non-executive employees. The grants, approved on September 18, 2025, cover 22,810 shares of common stock with an exercise price of $2.20 per share.

The stock options were awarded under Iovance's Amended and Restated 2021 Inducement Plan, which follows Nasdaq Listing Rule 5635(c)(4). The options vest over three years, with one-third vesting on the first employment anniversary and the remaining portions vesting quarterly over the following two years.

Iovance Biotherapeutics (NASDAQ: IOVA), una società biotecnologica specializzata nelle terapie TIL per pazienti affetti da cancro, ha concesso opzioni azionarie di incentivo a due nuovi dipendenti non esecutivi. Le assegnazioni, approvate il 18 settembre 2025, coprono 22.810 azioni ordinarie con un prezzo di esercizio di 2,20 USD per azione.

Le opzioni azionarie sono state conferite ai sensi del Piano di incentivo del 2021, come modificato e integrato di Iovance, che segue la Nasdaq Listing Rule 5635(c)(4). Le opzioni si maturano su un periodo di tre anni, con un terzo maturato al primo anniversario dell’assunzione e le porzioni rimanenti maturano trimestralmente nei due anni successivi.

Iovance Biotherapeutics (NASDAQ: IOVA), una empresa de biotecnología que se especializa en terapias TIL para pacientes con cáncer, ha otorgado opciones de acciones de incentivo a dos nuevos empleados no ejecutivos. Las adjudicaciones, aprobadas el 18 de septiembre de 2025, cubren 22.810 acciones ordinarias con un precio de ejercicio de $2.20 por acción.

Las opciones se otorgaron bajo el Plan de Incentivo 2021 enmendado y restaurado de Iovance, que sigue la Nasdaq Listing Rule 5635(c)(4). Las opciones se consolidan/ vencerán en un periodo de tres años, con un tercio adquirido en el primer aniversario de la contratación y las porciones restantes se consolidan trimestralmente durante los dos años siguientes.

아이오반스 바이오테크노로지스(Iovance Biotherapeutics, NASDAQ: IOVA), 암 환자를 위한 TIL 치료에 전문화된 생명공학 회사는 두 명의 신규 비상임 직원에게 유인 주식 옵션을 부여했습니다. 이 수여는 2025년 9월 18일 승인되었으며 주당 22,810주의 보통주를 커버하며 행사가격은 주당 2.20달러입니다.

해당 옵션은 Iovance의 수정 및 보완된 2021년 유인 계획에 따라 수여되었으며, 이는 나스닥 상장 규칙 5635(c)(4)을 따릅니다. 옵션은 3년 동안 vesting되며, 첫 고용 기념일에 3분의 1이 vesting되고 남은 부분은 이후 2년 동안 분기별로 vesting됩니다.

Iovance Biotherapeutics (NASDAQ: IOVA), une société de biotechnologie spécialisée dans les thérapies TIL pour les patients atteints de cancer, a accordé des options d’actions d’incitation à deux nouveaux employés non cadres. Les attributions, approuvées le 18 septembre 2025, couvrent 22 810 actions ordinaires avec un prix d’exercice de 2,20 USD par action.

Les options ont été attribuées dans le cadre du Plan d’incitation 2021 modifié et rétabli d’Iovance, qui respecte la Nasdaq Listing Rule 5635(c)(4). Les options se vestent sur une période de trois ans, avec un tiers qui se vest à la première anniversaire de l’embauche et les portions restantes se vestent trimestriellement au cours des deux années suivantes.

Iovance Biotherapeutics (NASDAQ: IOVA), ein Biotechnologieunternehmen, das sich auf TIL-Therapien für Krebspatienten spezialisiert hat, hat zwei neue nicht-exekutive Mitarbeitende mit Incentive-Aktienoptionen ausgestattet. Die Zuteilungen, genehmigt am 18. September 2025, betreffen 22.810 Stammaktien mit einem Ausübungspreis von 2,20 USD pro Aktie.

Die Optionen wurden gemäß Iovances geändertem und neu gefasstem 2021 Inducement Plan vergeben, der der Nasdaq Listing Rule 5635(c)(4) entspricht. Die Optionen vesten über drei Jahre, wobei ein Drittel am ersten Beschäftigungsjubiläum vestet und die verbleibenden Anteile in den folgenden zwei Jahren vierteljährlich vesten.

Iovance Biotherapeutics (NASDAQ: IOVA)، شركة تكنولوجيا حيوية تتخصص في علاجات TIL لمرضى السرطان، قد منحت خيارات أسهم تحفيزية لـموظفين جديدين غير تنفيذيين. تغطي المنح، التي تمت الموافقة عليها في 18 سبتمبر 2025، 22,810 سهماً عاديًا بسعر ممارسة قدره 2.20 دولارًا للسهم.

تم منح خيارات الأسهم وفقًا لـخطة التحفيز المعدلة لعام 2021 لدى Iovance، وتتبع قاعدة ناسداك للإدراج 5635(c)(4). تتفعل الخيارات خلال ثلاث سنوات، مع vesting ثالث عند الذكرى الأولى للتوظيف وتفعل الأجزاء المتبقية ربعياً خلال العامين التاليين.

Iovance Biotherapeutics(纳斯达克股票代码:IOVA),一家专注于针对癌症患者的TIL疗法的生物技术公司,已向两名新的非执行员工授予诱导性股票期权。该等授予经于2025年9月18日批准,覆盖 22,810 股普通股,行权价为 每股 2.20 美元

这些股票期权是依据 Iovance 的经修订并重申的 2021 诱导计划 授予,符合纳斯达克上市规则 5635(c)(4)。期权将在三年内分阶段归属,首次归属在雇佣周年日的三分之一,其余部分在随后的两年内按季度归属。

Positive
  • None.
Negative
  • None.

SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 18, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 22,810 shares of Iovance’s common stock to two new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 2023, February 26, 2024, and November 22, 2024, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $2.20, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150


FAQ

What stock options did Iovance Biotherapeutics (IOVA) grant to new employees in September 2025?

Iovance granted inducement stock options covering 22,810 shares to two new non-executive employees, with an exercise price of $2.20 per share.

What is the vesting schedule for Iovance's (IOVA) September 2025 inducement stock options?

The options vest over three years, with one-third vesting on the first employment anniversary and the remaining portions vesting in eight quarterly installments over the following two years.

Under which plan were Iovance's (IOVA) September 2025 inducement grants awarded?

The grants were awarded under Iovance's Amended and Restated 2021 Inducement Plan, which complies with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price for Iovance's (IOVA) September 2025 inducement stock options?

The exercise price is $2.20, which was the closing price of Iovance's common stock on September 18, 2025.
Iovance Biotherp

NASDAQ:IOVA

IOVA Rankings

IOVA Latest News

IOVA Latest SEC Filings

IOVA Stock Data

796.08M
331.59M
0.36%
69.34%
19.71%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN CARLOS